Metotrexato Accord

Methotrexate, the active ingredient in Metotrexato Accord, is an antimetabolite (folate antagonist) presented as a sterile solution for intra‑arterial, intramuscular or intravenous use. It is employed to manage autoimmune disorders and certain malignancies in adult and pediatric patients through targeted therapy and is often incorporated into combination regimens.

GNH USA supplies Metotrexato Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant units and pharmacies worldwide, ensuring quality‑assured product delivery and regulatory compliance across global markets.

Methotrexate is used in autoimmune and oncologic disease pathways to modulate cell proliferation and immune response.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: limits skin cell overgrowth and improves plaque appearance. - Acute lymphoblastic leukemia: interferes with malignant lymphoblast replication. - Non‑Hodgkin lymphoma: suppresses rapid tumor cell division. - Ectopic pregnancy: halts trophoblastic growth to allow non‑surgical resolution.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting. - Fatigue and general weakness. - Oral mucosal ulceration (mouth sores). - Mild elevation of liver enzymes. - Transient decrease in white blood cell count.

Serious or Rare Side Effects: - Severe hepatotoxicity or liver fibrosis. - Pulmonary toxicity, including interstitial pneumonitis. - Significant bone marrow suppression leading to anemia or infection risk. - Renal impairment or failure. - Life‑threatening infections due to immunosuppression.

Patients receiving methotrexate require careful monitoring and specific safety measures. - Monitor blood counts: perform regular complete blood count tests. - Assess liver function: schedule periodic liver enzyme evaluations. - Avoid use in pregnancy: methotrexate is contraindicated and requires effective contraception. - Adjust dose in renal impairment: reduce dosage or increase monitoring as kidney function declines. - Counsel on infection risk: advise prompt reporting of fever or signs of infection. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Methotrexate interacts with several medicines that can alter its safety or efficacy.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Penicillins and other antibiotics: may enhance bone‑marrow suppression. - Live vaccines: risk of severe infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Proton‑pump inhibitors: can raise methotrexate plasma levels. - Allopurinol: may increase risk of hematologic toxicity.